4.6 Review

Clearance of von Willebrand factor

期刊

JOURNAL OF THROMBOSIS AND HAEMOSTASIS
卷 11, 期 -, 页码 202-211

出版社

WILEY-BLACKWELL
DOI: 10.1111/jth.12226

关键词

glycosylation; metabolic clearance rate; polymorphism; single nucleotide; von Willebrand diseases; von Willebrand factor

资金

  1. Fondation pour la Recherche Medicale [FRM-SPF20101220866]
  2. Agence Nationale de la Recherche [ANR-11-BSV1-010-01]

向作者/读者索取更多资源

Quantitative deficiencies in von Willebrand factor (VWF) are associated with abnormal hemostasis that can manifest in bleeding or thrombotic complications. Consequently, many studies have endeavored to elucidate the mechanisms underlying the regulation of VWF plasma levels. This review focuses on the role of VWF clearance pathways. A summary of recent developments are provided, including results from genetic studies, the relationship between glycosylation and VWF clearance, the contribution of increased VWF clearance to the pathogenesis of von Willebrand disease and the identification of VWF clearance receptors. These different studies converge in their conclusion that VWF clearance is a complex phenomenon that involves multiple mechanisms. Deciphering how such different mechanisms coordinate their role in this process is but one of the remaining challenges. Nevertheless, a better insight into the complex clearance pathways of VWF may help us to better understand the clinical implications of aberrant clearance in the pathogenesis of von Willebrand disease and perhaps other disorders as well as aid in developing alternative therapeutic approaches.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor

Elena Barbon, Charlotte Kawecki, Solenne Marmier, Aboud Sakkal, Fanny Collaud, Severine Charles, Giuseppe Ronzitti, Caterina Casari, Olivier D. Christophe, Cecile V. Denis, Peter J. Lenting, Federico Mingozzi

Summary: Von Willebrand disease (VWD), the most common inherited bleeding disorder, has limited efficacy with current liver-directed gene therapy. This study developed a gene therapy strategy using an optimized AAV vector and endothelial-targeting peptide to deliver the VWF gene into endothelial cells, achieving long-term expression.

GENE THERAPY (2023)

Article Cardiac & Cardiovascular Systems

The VWF/LRP4/αVβ3-axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells

Jeremy Lagrange, Morel E. Worou, Jean-Baptiste Michel, Alexandre Raoul, Melusine Didelot, Vincent Muczynski, Paulette Legendre, Francois Plenat, Guillaume Gauchotte, Marc-Damien Lourenco-Rodrigues, Olivier D. Christophe, Peter J. Lenting, Patrick Lacolley, Cecile Denis, Veronique Regnault

Summary: VWF induces VSMC proliferation through A2 domain binding to LRP4 receptor and integrin alpha(v)beta(3) signaling. These findings provide new insights into the mechanisms that drive physiological repair and pathological hyperplasia of the arterial vessel wall.

CARDIOVASCULAR RESEARCH (2022)

Article Hematology

The Proteolytic Inactivation of Protein Z-Dependent Protease Inhibitor by Neutrophil Elastase Might Promote the Procoagulant Activity of Neutrophil Extracellular Traps in Sepsis

Elsa P. Bianchini, Mahita Razanakolona, Julie Helms, Fouzia Zouiti, Amelie Couteau-Chardon, Viviana Marin-Esteban, Luc de Chaisemartin, Allan De-Carvalho, Roselyne Bironien, Sylvie Chollet-Martin, Cecile Denis, Jean-Luc Diehl, Marc Vasse, Ferhat Meziani, Delphine Borgel

Summary: The study assessed plasma ZPI antigen levels in patients with septic shock, finding a significant elevation in ZPI concentration in patients compared to healthy controls, regardless of DIC presence. Experimental evidence revealed the involvement of NE in ZPI inactivation during sepsis, proposing a novel mechanism for the procoagulant activity of NETs in immunothrombosis.

THROMBOSIS AND HAEMOSTASIS (2022)

Editorial Material Hematology

How to keep the factor VIII/von Willebrand factor complex in the circulation

Cecile V. Denis, Peter J. Lenting

HAEMATOLOGICA (2022)

Article Hematology

A thrombopoietin receptor agonist to rescue an unusual platelet transfusion-induced reaction in a p.V1316M-associated von Willebrand disease type 2B patient

Caterina Casari, Remi Favier, Paulette Legendre, Alexandre Kauskot, Frederic Adam, Veronique Picard, Peter J. Lenting, Cecile Denis, Valerie Proulle

Summary: This report describes the successful treatment of splenic injury in a patient with p.V1316M-associated VWD2B and chronic thrombocytopenia using nonoperative management and a combination of VWF replacement therapy and platelet transfusions relayed by TPO-RA.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2022)

Article Hematology

A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD

Claire Kizlik-Masson, Ivan Peyron, Stephane Gangnard, Gaelle Le Goff, Solen M. Lenoir, Sandra Damodaran, Marie Clavel, Stephanie Roullet, Veronique Regnault, Antoine Rauch, Flavien Vincent, Emmanuelle Jeanpierre, Annabelle Dupont, Catherine Ternisien, Thibault Donnet, Olivier D. Christophe, Eric van Belle, Cecile Denis, Caterina Casari, Sophie Susen, Peter J. Lenting

Summary: A nanobody (KB-VWF-D3.1) is identified to distinguish proteolyzed and non-proteolyzed VWF and monitor VWF degradation levels. Reduced intact-VWF levels are observed in patients with von Willebrand disease, aortic stenosis, and patients receiving mechanical circulatory support.
Article Hematology

Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models

Stephanie Roullet, Norman Luc, Julie Rayes, Jean Solarz, Dante Disharoon, Andrew Ditto, Emily Gahagan, Christa Pawlowski, Thibaud Sefiane, Frederic Adam, Caterina Casari, Olivier D. Christophe, Michael Bruckman, Peter J. Lenting, Anirban Sen Gupta, Cecile Denis

Summary: The lack of innovation in von Willebrand disease (VWD) is due to the complexity and heterogeneity of the disease and a lack of recognition of the impact of bleeding symptoms experienced by patients. This study proposes a new approach using synthetic platelet (SP) nanoparticles for the treatment of VWD-2B and severe VWD. The results show that SP can improve thrombus formation and reduce blood loss in VWD-2B and VWF-KO mice.
Article Cardiac & Cardiovascular Systems

Shear Forces Induced Platelet Clearance Is a New Mechanism of Thrombocytopenia

Antoine Rauch, Annabelle Dupont, Mickael Rosa, Maximilien Desvages, Christina Le Tanno, Johan Abdoul, Melusine Didelot, Alexandre Ung, Richard Ruez, Emmanuelle Jeanpierre, Melanie Daniel, Delphine Corseaux, Hugues Spillemaeker, Julien Labreuche, Benedicte Pradines, Natacha Rousse, Peter J. Lenting, Mouhamed D. Moussa, Andre Vincentelli, Jean-Claude Bordet, Bart Staels, Flavien Vincent, Cecile V. Denis, Eric Van Belle, Caterina Casari, Sophie Susen

Summary: Thrombocytopenia is consistently observed in ECMO patients, with a time-dependent decrease in platelet count, GP Ib alpha shedding, and increased soluble GP Ib alpha levels. Shedding of GP Ib alpha is dependent on rheological conditions, with higher rates at high-flow speeds.

CIRCULATION RESEARCH (2023)

Article Hematology

Angiopoietin-2 binds to multiple interactive sites within von Willebrand factor

Alexis Texier, Peter J. Lenting, Cecile Denis, Stephanie Roullet, Olivier D. Christophe

Summary: This study reveals the binding between von Willebrand factor and angiopoietin-2, with angiopoietin-2 enhancing the binding of von Willebrand factor to angiopoietin-1.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2023)

Article Hematology

MAGT1 deficiency in XMEN disease is associated with severe platelet dysfunction and impaired platelet glycoprotein N-glycosylation

Alexandre Kauskot, Coralie Mallebranche, Arnaud Bruneel, Francois Fenaille, Jean Solarz, Toscane Viellard, Miao Feng, Christelle Reperant, Jean-Claude Bordet, Sophie Cholet, Cecile Denis, Genevieve McCluskey, Sylvain Latour, Emmanuel Martin, Isabelle Pellier, Dominique Lasne, Delphine Borgel, Sven Kracker, Alban Ziegler, Marie Tuffigo, Benjamin Fournier, Charline Miot, Frederic Adam

Summary: XMEN disease, caused by loss-of-function mutations in the MAGT1 gene, is associated with platelet dysfunction and defective N-glycosylation, which may explain the bleeding events in patients with XMEN disease.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Article Hematology

Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab

Melissa Bou-Jaoudeh, Angelina Mimoun, Sandrine Delignat, Ivan Peyron, Ladislas Capdevila, Victoria Daventure, Claire Deligne, Jordan D. Dimitrov, Olivier D. Christophe, Cecile V. Denis, Peter J. Lenting, Valerie Proulle, Sebastien Lacroix-Desmazes

Summary: This study investigated the impact of IdeS treatment in inhibitor-positive HA mice injected with emicizumab. The results showed that IdeS efficiently eliminated anti-FVIII IgG and restored the hemostatic efficacy of exogenous FVIII, unaffected by the presence of emicizumab and polyclonal human IgG in the mice.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Article Hematology

Identification of von Willebrand factor D4 domain mutations in patients of Afro-Caribbean descent: In vitro characterization

Marie-Daniela Dubois, Ivan Peyron, Olivier-Nicolas Pierre-Louis, Serge Pierre-Louis, Johalene Rabout, Pierre Boisseau, Annika de Jong, Sophie Susen, Jenny Goudemand, Remi Neviere, Pascal Fuseau, Olivier D. Christophe, Peter J. Lenting, Cecile Denis, Caterina Casari

Summary: This study reports two mutations in the D4 domain of VWF that induce combined qualitative and quantitative defects. One mutation leads to almost complete intracellular retention of the protein, while the other mutation results in reduced binding to collagen and platelet receptors.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2022)

暂无数据